Pharmacyclics Earns Neutral Rating from Analysts at SunTrust (PCYC)
Several other analysts have also recently commented on the stock. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $155.33.
In other Pharmacyclics news, COO Maky Zanganeh sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $121.75, for a total value of $1,461,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Pharmacyclics (NASDAQ:PCYC) traded down 2.97% on Thursday, hitting $119.30. 668,812 shares of the company’s stock traded hands. Pharmacyclics has a 52 week low of $82.51 and a 52 week high of $154.89. The stock has a 50-day moving average of $115.5 and a 200-day moving average of $107.1. The company has a market cap of $8.980 billion and a P/E ratio of 109.87.
Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Thursday, July 31st. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. The company’s quarterly revenue was up 106.6% on a year-over-year basis. On average, analysts predict that Pharmacyclics will post $0.36 earnings per share for the current fiscal year.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Receive News & Ratings for Pharmacyclics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmacyclics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.